Mitapro 7.5 Tablet

About Mitapro 7.5 Tablet

Mitapro 7.5 is a 7.5 mg tablet made by Renata PLC. It contains mirtazapine, an atypical anti-depressant used in the treatment of major depressive disorder in adults.

There are 20 brands of Mirtazapine listed in Bangladesh. The lowest listed price is Rapine 7.5 Tablet at ৳ 6 per unit.

What is Mitapro 7.5 Tablet?

Mitapro 7.5 is an oral tablet containing 7.5 mg of mirtazapine, an atypical anti-depressant. It is prescribed for major depressive disorder in adults. Mirtazapine is thought to work by increasing certain chemical activity in the brain, though the exact way it relieves depression is not fully known. It can cause drowsiness and increased appetite. Treatment should be supervised by a doctor, who will decide the right dose and course for each person. Do not start, stop or change the medicine on your own.

Uses of Mitapro 7.5

Mitapro 7.5 is used to treat major depressive disorder in adults. It belongs to a group of medicines called atypical anti-depressants. It is not recommended for use in children. Your doctor will assess your condition and decide whether this medicine is suitable for you. Ask your doctor if you have questions about what it treats or how long you may need it.

How to use Mitapro 7.5

Take Mitapro 7.5 exactly as your doctor tells you. The doctor decides the dose and how long you take it, and may adjust it over time. Swallow the tablet as directed. Do not change the dose or stop the medicine without talking to your doctor first, since stopping suddenly can cause problems. If you miss a dose, ask your doctor or pharmacist what to do.

Side effects of Mitapro 7.5

Common side effects of mirtazapine include dizziness, drowsiness, dry mouth, increased appetite and weight gain. Because it can make you drowsy and affect judgment and motor skills, be careful with activities like driving until you know how it affects you. Tell your doctor if side effects bother you or do not go away. Seek medical help if you notice unusual changes in behaviour or mood, or any serious reaction.

Safety and precautions

Before taking Mitapro 7.5, tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. It is not for people allergic to mirtazapine or its ingredients, or for people taking a monoamine oxidase inhibitor (MAOI) or who have taken one recently. Avoid alcohol and diazepam while taking it. Tell your doctor about all other medicines you use. Be alert for worsening depression, anxiety, agitation, restlessness or suicidal thoughts, especially early in treatment or when the dose changes, and report them promptly. Your doctor will decide if it is safe for you.

Frequently asked questions

How should I take Mitapro 7.5?

Take Mitapro 7.5 exactly as your doctor prescribes. The doctor decides the dose and how long you take it. Swallow the tablet as directed and do not change the dose or stop the medicine on your own. If you miss a dose, ask your doctor or pharmacist what to do.

What is Mitapro 7.5 used for and what kind of medicine is it?

Mitapro 7.5 is a 7.5 mg tablet containing mirtazapine, an atypical anti-depressant. It is used to treat major depressive disorder in adults. It is not recommended for children. Your doctor will decide whether it is suitable for your condition.

Which medicines may interact with Mitapro 7.5?

Mitapro 7.5 can interact with monoamine oxidase inhibitors (MAOIs) and other serotonergic medicines such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol and St. John's wort. It may also affect carbamazepine, phenytoin or cimetidine. Avoid alcohol and diazepam. Tell your doctor about all medicines you take.

What should I tell my doctor before starting Mitapro 7.5?

Tell your doctor if you are pregnant, plan to become pregnant or are breastfeeding, and about any allergy to mirtazapine. Also mention all other medicines you use, including MAOIs, and whether you drink alcohol. Your doctor will decide if Mitapro 7.5 is safe for you.

Indications

Mirtazapine Tablets are indicated for the treatment of major depressive disorder (MDD).

Pharmacology

Pharmacodynamics: The mechanism of action of Mirtazapine as with other drugs effective in the treatment of major depressive disorder is unknown. Evidence gathered in preclinical studies suggests that Mirtazapine enhances central noradrenergic and serotonergic activity. These studies have shown that Mirtazapine acts as an antagonist at central presynaptic α2-adrenergic inhibitory autoreceptors and heteroreceptors, an action that is postulated to result in an increase in central noradrenergic and serotonergic activity. Mirtazapine is a potent antagonist of 5- HT2 and 5-HT3 receptors. Mirtazapine has no significant affinity for the 5-HT1A and 5-HT1B receptors. Mirtazapine is a potent antagonist of histamine (H1) receptors, a property that may explain its prominent sedative effects. Mirtazapine is a moderate peripheral α1-adrenergic antagonist, a property that may explain the occasional orthostatic hypotension reported in association with its use. Mirtazapine is a moderate antagonist at muscarinic receptors, a property that may explain the relatively low incidence of anticholinergic side effects associated with its use.

Pharmacokinetics: After oral administration of Mirtazapine tablets, the active constituent mirtazapine is rapidly and well-absorbed, reaching peak plasma levels after about 2 hours. Binding of mirtazapine to plasma proteins is approximately 85%. The mean half-life of elimination is 20-40 hours; (26 hours in males, 37 hours in females). The half-life of elimination is sufficient to justify once-a-day dosing. Mirtazapine displays linear pharmacokinetics within the recommended dose range. Mirtazapine is extensively metabolized and eliminated via the urine and faeces four days. Major pathways of biotransformation are demethylation and oxidation followed by conjugation.

Dosage & Administration

Adult dose: The recommended starting dose for Mirtazapine tablets is 15 mg/day, administered in a single dose, preferably in the evening or prior to sleep. The effective dose range was generally 15 to 45 mg/day and the patients not responding to the initial 15 mg dose may benefit from dose increases up to a 30 mg to maximum of 45 mg/day. Mirtazapine has an elimination half-life of approximately 20 to 40 hours; therefore, dose changes should be made at intervals of less than 1 to 2 weeks in order to allow sufficient time for the therapeutic response to a given dose.

Use in children: Use in children are not recommended to Mirtazapine.

Missed Dose: If anyone misses a dose of mirtazapine, take it as soon as remember unless it is close to when the next dose is due. If anyone missed a dose of medication and it is close to the time of next dose, skip the missed dose and should take next dose at the regularly scheduled time. One should not take double or more than prescribed dose.

Interaction

Mirtazapine has clinically significant drug-drug interactions with Monoamine Oxidase Inhibitors (MAOI) & other serotonergic drugs such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St. John's wort. Mirtazapine may interrupt the metabolism or activity of Carbamazepine, Phenytoin or Cimetidine. Patient should avoid Alcohol & Diazepam while taking Mirtazapine.

Contraindications

Hypersensitivity: Mirtazapine is contraindicated in patients with a known hypersensitivity to Mirtazapine or to any of the excipients.

Monoamine Oxidase Inhibitors: The concomitant use of Mirtazapine and a monoamine oxidase (MAO) inhibitor is contraindicated. Mirtazapine should not be used within 14 days of initiating or discontinuing therapy with a monoamine oxidase inhibitor (MAOI).

Side Effects

The most common side effects of Mirtazapine are dizziness, drowsiness, dry mouth, increased appetite, weight gain etc.

Pregnancy & Lactation

Pregnancy Category-C. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during Mirtazapine therapy. Patients should be advised to notify their physician if they are breastfeeding an infant.

Precautions & Warnings

Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Patients who are to receive Mirtazapine should be warned about the risk of developing agranulocytosis. Mirtazapine may impair judgment, thinking, and particularly, motor skills, because of its prominent sedative effect. Clinically significant ALT (SGPT) elevations (≥3 times the upper limit of the normal range) may occur.

Storage Conditions

Keep away from light and moisture. Store below 30º C. Keep all medicine out of the reach of children.

Alternative brands of Mirtazapine

Other brands with the same generic name, cheapest first.

See all 20 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.